Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.

Koshy, Anoop N; Giustino, Gennaro; Sartori, Samantha; Hooda, Amit; Feng, Yihan; Snyder, Clayton; Dasgupta, Shabitri; Kumar, Kartik R; Krishnamoorthy-Melarcode, Parasuram; Sweeny, Joseph; Khera, Sahil; Serrao, Gregory W; Sharma, Raman; Dangas, George; Kini, Annapoorna S; Mehran, Roxana; Sharma, Samin K

doi:10.4244/EIJ-D-22-00654

Title

Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.

Publication Date

2023-01-19

Author(s)

Koshy, Anoop N

Giustino, Gennaro

Sartori, Samantha

Hooda, Amit

Feng, Yihan

Snyder, Clayton

Dasgupta, Shabitri

Kumar, Kartik R

Krishnamoorthy-Melarcode, Parasuram

Sweeny, Joseph

Khera, Sahil

Serrao, Gregory W

Sharma, Raman

Dangas, George

Kini, Annapoorna S

Mehran, Roxana

Sharma, Samin K

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.4244/EIJ-D-22-00654

Abstract

Potent P2Y12 inhibitors such as ticagrelor and prasugrel are superior to clopidogrel in acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI). Whether this benefit extends to a patient population with chronic coronary syndromes (CCS) is unclear.

Link

link

Citation

EuroIntervention 2023; 18(15)

Jornal Title

EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

ISSN

1969-6213

Austin Health

Files: